Analystreport

PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) had its "buy" rating re-affirmed by analysts at HC Wainwright.

PhaseBio Pharmaceuticals, Inc.  (PHAS) 
Last phasebio pharmaceuticals, inc. earnings: 3/30 08:01 am Check Earnings Report